Study on BMS-986504 for Advanced or Metastatic Non-small Cell Lung Cancer with Specific Genetic Deletion

Inclusion Criteria

• Have a confirmed diagnosis of Non-small Cell Lung Cancer (NSCLC) with a specific genetic deletion called homozygous MTAP deletion.
• Be willing to provide a tumor sample for testing.
• Have advanced or metastatic NSCLC that cannot be cured and has worsened after previous treatments.
• Have at least one tumor that can be measured by scans.
• Show evidence of cancer growth on recent scans after the last treatment.
• Be in good overall health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Be 18 years or older, or the legal age of consent in the area where the study is conducted.
• Be able to swallow tablets whole without chewing or crushing them.

Exclusion Criteria

• Have active cancer spread to the brain or a condition called carcinomatous meningitis.
• Have digestive issues that could affect the absorption of the study drug or make it difficult to swallow pills.
• Have previously been treated with drugs that inhibit PRMT5 or MAT2A.
• Have a known severe allergy to the study drug or any of its ingredients.
• Other specific criteria may apply as defined by the study protocol.